enGene Holdings (ENGN) 2025 Conference June 04, 2025 11:05 AM ET Speaker0 Well, thank you very much. It's a delight to be here, and I'm grateful for this opportunity to speak about NGIN, which is a non viral genetic medicines company that's at a very important stage in our life cycle. I'm looking forward to sharing more about that with all of you. So again, thank you to the conference organizers for this opportunity. As you will expect, I'm gonna be making some forward looking statements during today's pres ...

enGene Holdings (ENGN) 2025 Conference May 05, 2025 02:00 PM ET Speaker0 For our next presentation, it's from NGIN, and we have the pleasure of having Ron Cooper, the CEO, here to present for us. So take it away, Ron. Thank you. Speaker1 Well, good afternoon, everybody. It's a real pleasure to be here. You know, first of all, thanks to the conference organizers. It's great to be back in back in Canada. NGEN is a company form formed in Canada. Our headquarters is in Montreal. Our labs are there, and we have ...

enGene (NASDAQ: ENGN ) is a small Canadian company that develops genetic medicines for bladder cancer. The company came to the market through a SPAC, and it has a platform.About the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For investors requiring hands-on support, our in-house expert ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 19:Nova Ltd. (NVMI) : This semiconductor equipment company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.3% over the last 60 days.Nova's shares gained 56.8% over the last three months compared with the S&P 500’s advanced of 3.5%. The company possesses a Momentum Score of A.Freshworks Inc. (FRSH) : This software development company has a ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:GE Aerospace (GE) : This manufacturer of aircraft engines, components and aircraft mechanical systems has seen the Zacks Consensus Estimate for its current year earnings increasing 3.9% over the last 60 days.Oportun Financial Corporation (OPRT) : This financial services provider has seen the Zacks Consensus Estimate for its current year earnings increasing 9.2% over the last 60 days.enGene Holdings Inc. (ENGN) : This clinical-stage biot ...

enGene Holdings (ENGN) FY 2025 Conference February 11, 2025 08:40 AM ET Company Participants Alex Nichols - Chief Strategy & Operations OfficerRyan Daws - CFO Conference Call Participants Leland Gershell - Managing Director - Senior Biotechnology Analyst Leland Gershell Great. Good morning, everyone, or good afternoon, depending where you may be. Welcome back to another session here at, Oppenheimer's thirty fifth annual, Healthcare Life Sciences annual conference. I'm Leland Grischell, one of the biotech an ...

Shares of enGene Holdings Inc. (ENGN) have gained 8% over the past four weeks to close the last trading session at $8.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $27.44 indicates a potential upside of 238.8%.The average comprises nine short-term price targets ranging from a low of $16 to a high of $37, with a standard deviation of $7.38. While the lowest estimate indicat ...

enGene Holdings Inc. (ENGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by t ...

enGene Holdings (NASDAQ: ENGN ) is a biotech focused mainly on the development of gene therapies, with their first shot on goal being in specific forms of bladder cancer. Through the use of plasmid technology, the company hopes to demonstrate that non-viralI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due dili ...

Group 1 - enGene Holdings Inc. (ENGN) has experienced a significant decline of 16.9% over the past four weeks, but it is now positioned for a potential trend reversal as it is in oversold territory [1] - The Relative Strength Index (RSI) for ENGN is currently at 26.43, indicating that the heavy selling pressure may be exhausting itself, suggesting a possible reversal in the stock's trend [4] - There is strong consensus among Wall Street analysts that ENGN will report better earnings than previously predicted, with a 2.3% increase in the consensus EPS estimate over the last 30 days [5] Group 2 - ENGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for price appreciation in the near term [5]